Top Midday Gainers

MT Newswires Live

2 hours ago

Omeros (OMER) said Wednesday the US Food and Drug Administration has approved Yartemlea to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy, a complication of stem-cell transplants.

Shares of the healthcare firm increased nearly 80% as intraday trading volume jumped to nearly 20.7 million, versus a daily average of roughly 3.7 million.

Edgewise Therapeutics (EWTX) rose roughly 21% after the company said it completed parts B and C of a phase 2 trial of EDG-7500 in patients with obstructive and nonobstructive hypertrophic cardiomyopathy and reported favorable interim safety results from its ongoing part D study.

Trading volume rose to 2.5 million from a daily average of about 1.3 million.

Sanofi (SNY) on Wednesday agreed to buy infectious disease vaccine maker Dynavax Technologies (DVAX) in a deal with an equity value of about $2.2 billion, as the company aims to strengthen its adult immunization portfolio.

Shares of Dynavax Technologies gained about 38% as intraday trading volume climbed to about 24.8 million from a daily average of about 1.6 million.

Price: 26.34, Change: +4.59, Percent Change: +21.13

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2594406333"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2594406333\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2594406333?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-25 01:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594406333","market":"nz","top_or_hot":-1,"title":"Top Midday Gainers","media":"MT Newswires Live","content":"<html><body><p> Omeros (OMER) said Wednesday the US Food and Drug Administration has approved Yartemlea to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy, a complication of stem-cell transplants.</p><p>Shares of the healthcare firm increased nearly 80% as intraday trading volume jumped to nearly 20.7 million, versus a daily average of roughly 3.7 million.</p><p>Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (EWTX) rose roughly 21% after the company said it completed parts B and C of a phase 2 trial of EDG-7500 in patients with obstructive and nonobstructive hypertrophic cardiomyopathy and reported favorable interim safety results from its ongoing part D study.</p><p>Trading volume rose to 2.5 million from a daily average of about 1.3 million.</p><p><a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) on Wednesday agreed to buy infectious disease vaccine maker Dynavax Technologies (DVAX) in a deal with an equity value of about $2.2 billion, as the company aims to strengthen its adult immunization portfolio.</p><p>Shares of Dynavax Technologies gained about 38% as intraday trading volume climbed to about 24.8 million from a daily average of about 1.6 million.</p><p>Price: 26.34, Change: +4.59, Percent Change: +21.13</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Gainers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Gainers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-25 01:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Omeros (OMER) said Wednesday the US Food and Drug Administration has approved Yartemlea to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy, a complication of stem-cell transplants.</p><p>Shares of the healthcare firm increased nearly 80% as intraday trading volume jumped to nearly 20.7 million, versus a daily average of roughly 3.7 million.</p><p>Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (EWTX) rose roughly 21% after the company said it completed parts B and C of a phase 2 trial of EDG-7500 in patients with obstructive and nonobstructive hypertrophic cardiomyopathy and reported favorable interim safety results from its ongoing part D study.</p><p>Trading volume rose to 2.5 million from a daily average of about 1.3 million.</p><p><a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) on Wednesday agreed to buy infectious disease vaccine maker Dynavax Technologies (DVAX) in a deal with an equity value of about $2.2 billion, as the company aims to strengthen its adult immunization portfolio.</p><p>Shares of Dynavax Technologies gained about 38% as intraday trading volume climbed to about 24.8 million from a daily average of about 1.6 million.</p><p>Price: 26.34, Change: +4.59, Percent Change: +21.13</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2594406333","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2594406333","pubTimestamp":1766596978,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Omeros  said Wednesday the US Food and Drug Administration has approved Yartemlea to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy, a complication of stem-cell transplants.Shares of the healthcare firm increased nearly 80% as intraday trading volume jumped to nearly 20.7 million, versus a daily average of roughly 3.7 million.Edgewise Therapeutics  rose roughly 21% after the company said it completed parts B and C of a phase 2 trial of EDG-7500 in patients with obstructive and nonobstructive hypertrophic cardiomyopathy and reported favorable interim safety results from its ongoing part D study.Trading volume rose to 2.5 million from a daily average of about 1.3 million.Sanofi  on Wednesday agreed to buy infectious disease vaccine maker Dynavax Technologies  in a deal with an equity value of about $2.2 billion, as the company aims to strengthen its adult immunization portfolio.Shares of Dynavax Technologies gained about 38% as intraday trading volume clim","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","BK4539":"次新股","BK4139":"生物科技","DYNA":"Dynastar Holdings, Inc.","OMER":"奥麦罗制药","BK4081":"电力公用事业","DVAX":"德纳维制药","BK4007":"制药","SNY":"赛诺菲安万特","BK4588":"碎股","EWTX":"Edgewise Therapeutics, Inc."},"translate_title":"午盘涨幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWTX":1,"SNY":1,"DYNA":0.9,"DVAX":1,"OMER":1},"content_text":"Omeros (OMER) said Wednesday the US Food and Drug Administration has approved Yartemlea to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy, a complication of stem-cell transplants.Shares of the healthcare firm increased nearly 80% as intraday trading volume jumped to nearly 20.7 million, versus a daily average of roughly 3.7 million.Edgewise Therapeutics (EWTX) rose roughly 21% after the company said it completed parts B and C of a phase 2 trial of EDG-7500 in patients with obstructive and nonobstructive hypertrophic cardiomyopathy and reported favorable interim safety results from its ongoing part D study.Trading volume rose to 2.5 million from a daily average of about 1.3 million.Sanofi (SNY) on Wednesday agreed to buy infectious disease vaccine maker Dynavax Technologies (DVAX) in a deal with an equity value of about $2.2 billion, as the company aims to strengthen its adult immunization portfolio.Shares of Dynavax Technologies gained about 38% as intraday trading volume climbed to about 24.8 million from a daily average of about 1.6 million.Price: 26.34, Change: +4.59, Percent Change: +21.13","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}